0.7762
2.98%
-0.0238
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World
Quince Therapeutics CEO acquires $107k in company stock - Investing.com
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily
Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News
Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News
Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena
Phase III data on Quince Therapeutics’ EryDex - The Pharma Letter
Quince Therapeutics reports progress in A-T treatment study - Investing.com
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - StockTitan
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - Business Wire
Quince Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Market Resilience: Quince Therapeutics Inc (QNCX) Finishes Weak at 0.58, Down -16.54 - The Dwinnex
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - InvestorPlace
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - StockTitan
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - Business Wire
Quince Therapeutics (NASDAQ:QNCX) Trading Up 2.6% - Defense World
Reviewing Genenta Science (NASDAQ:GNTA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial - Clinical Trials Arena
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial - Yahoo! Voices
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia ... - Business Wire
Quince Therapeutics (NASDAQ:QNCX) versus Kymera Therapeutics (NASDAQ:KYMR) Critical Review - Defense World
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Yahoo Finance
Quince Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Quince Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com
Quince Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Quince Therapeutics faces Nasdaq delisting over share price - Investing.com
Stock Surge: Quince Therapeutics Inc (QNCX) Closes at 0.68, Marking a -4.23 Increase/Decrease – DWinneX - The Dwinnex
Critical Review: Autolus Therapeutics (NASDAQ:AUTL) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - br.ADVFN.com
O-I Glass, Inc. (NYSE:OI) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Comparing Ikena Oncology (NASDAQ:IKNA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex - Pharmaceutical Technology
Quince Therapeutics (NASDAQ:QNCX) Trading 5.7% Higher - Defense World
Ascend Wellness (OTC:AAWH) Shares Down 6.5% - Defense World
Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Rises By 7.1% - Defense World
Mandalay Resources (OTCMKTS:MNDJF) Stock Price Down 3% - Defense World
FDA fast tracks Quince Therapeutics' EryDex for A-T treatment - Investing.com South Africa
FDA fast tracks Quince Therapeutics' EryDex for A-T treatment - Investing.com India
FDA fast tracks Quince Therapeutics' EryDex for A-T treatment By Investing.com - Investing.com
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System - StockTitan
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System - Yahoo Finance
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock ... - Yahoo Finance
Understanding the Risks of Investing in Quince Therapeutics Inc (QNCX) – Knox Daily - Knox Daily
Trivest Advisors Ltd Reduces Stock Position in NVIDIA Co. (NASDAQ:NVDA) - Defense World
Quince Therapeutics Inc [QNCX] Investment Guide: What You Need to Know – Knox Daily - Knox Daily
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results - Business Wire
Contrasting Vitro Diagnostics (OTCMKTS:VODG) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
9 Short Squeeze Stocks That Could Take Off in August - MSN
GXO appoints Rui Marques as Managing Director in Spain and Portugal By Investing.com - Investing.com India
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference - Business Wire
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference - Yahoo Finance
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 ... - Yahoo Finance
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 - InvestorPlace
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - Business Wire
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 - Yahoo Finance
Gaithersburg's Cartesian Therapeutics moving headquarters to Frederick following Selecta Biosciences merger ... - Washington Business Journal
자본화:
|
볼륨(24시간):